
Opinion|Videos|April 15, 2024
Monitoring and Mitigating Adverse Events
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Exploring general principles and practices for monitoring and mitigating adverse events in patients with chronic GvHD treated with systemic agents, and determining when dose modification or treatment discontinuation is warranted.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































